Both β‐glucan and quercetin were confirmed to inhibit colon cancer when they were used alone (Kee et al., 2016; Zielke et al., 2017), and our present results further showed that alternating the consumption of β‐glucan and quercetin reduced the mortality rate by 12%, somewhat alleviating CRC. Here, PPIB is linked to colorectal carcinoma.